China Oncology ›› 2016, Vol. 26 ›› Issue (1): 67-72.doi: 10.3969/j.issn.1007-3969.2016.01.011

Previous Articles     Next Articles

The impact of lymph node metastatic rate on clinical outcome following 131I therapy in patients with papillary thyroid carcinoma

GAO Wen1,2, LIANG Jun1, ZHAO Teng1, LI Jiao1, LIN Yansong2   

  1. 1.Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China; 2.Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
  • Online:2016-01-30 Published:2016-02-26
  • Contact: LIN Yansong E-mail: linys@pumch.cn

Abstract: Background and purpose: This study aimed to investigate the relationship between lymph node metastatic rate (LR) and response to radioiodine therapy in patients with papillary thyroid carcinoma (PTC). Methods: A total number of 143 PTC patients after radioiodine therapy were included and classified into 4 groups [Ⅰ(0%-10%),Ⅱ(>10%-25%), Ⅲ(>25%-50%), Ⅳ(>50%)] according to the lymph node metastatic rate, and the responses to initial radioiodine therapy after a median follow-up period of 20.7 months were evaluated. They were classified into 4 groups [excellent response (ER), indeterminate response (IDR), biochemical incomplete response (BIR), and structural incomplete response (SIR)] according to the guideline proposed by 2015 American Thyroid Association. One-Way analysis of variance, χ2 test and Kruskal-Wallis test were used to evaluate the differences in basic clinicopathological features and clinical responses among the 4 groups. The ROC curve was analyzed to evaluate the clinical value of lymph node metastatic rate for predicting ER and optimal cut-off point. Results: There were no significant differences in gender and T-stage among 4 groups (P>0.05). However,Ⅰ group was significantly older than the other 3 groups (P=0.001). With the increase of lymph node metastatic rate, the number of ER cases decreased, while cases of BIR and SIR generally increased. Compared with the other 3 groups, less cases of ER (27.8%), while more BIR (27.8%) or SIR (11.1%) were observed in group Ⅳ (H=18.816, P=0.000). Cut-off value of lymph node involved rate was 52.27%, with a better specificity of predicting ER. Area under the ROC curve was 0.668. Conclusion: The higher lymph node metastatic rate in patients with PTC, the worse clinical outcome it could be. A cut-off value of lymph node metastatic rate 52.27% is a specific independent predictor for the clinical outcome in PTC patients treated with radioiodine therapy.

Key words: Papillary thyroid carcinoma, Lymph node metastatic rate, Radioiodine remnant ablation, Clinical outcome